Skip to main content
OpenTrials
Completed

NCT Number: NCT03784300

A Safety Study of PTI-125 in Healthy Volunteers

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer Disease, Early Onset Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Worldwide Clinical Trials

San Antonio, Texas, 78217, United States

About this study

This was a Phase I, single center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy volunteers, 18 to 45 years of age. A total of twenty-four (24) subjects were enrolled into the study in one of three dose cohorts. Each cohort contained eight subjects; six subjects received PTI-125 and two received placebo. Three doses of PTI-125 oral solution (50, 100, and 200 mg) or placebo solution were administered to respective cohorts.

The study included a screening period (Day -28 to Day -1), an inpatient treatment period (Day 0 through Day 4), and a follow-up visit (Day 7). Subjects reported to the clinic on the day before dosing and were randomized to receive either a single dose of orally administered PTI-125 or placebo. Each dose was administered following an overnight fast of at least 10 hours.

For each dose level, dosing was staggered such that two subjects (one active and one placebo) were dosed prior to the rest of the group. After a minimum of 24 hours and review of all 24-hour safety assessments (electrocardiogram [ECG], a brief physical examination, vital signs, and laboratory assessments) an independent Data Safety Monitoring Board/Data Monitoring Committee (DSMB/DMC) determined whether the remaining 6 subjects were to be dosed.

Pharmacokinetic blood samples were obtained prior to dosing and at specified intervals during the study (0-72 hours post-dose). Blood draws for laboratory testing were performed prior to dosing and at 24 hours post dose. After safety assessments of ECG, vital signs, and a brief physical exam at 72 hours, subjects were discharged from the clinic and returned 7 days post-dose for a final safety assessment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects between 18 and 45 years of age, inclusive.
  • The subject has a body mass index (BMI) within 18-30 kg/m2 (inclusive).
  • The subject is in good health as determined by medical history and physical examination and clinical laboratory parameters.
  • The subject is willing and able to speak, read, and understand English and provide written informed consent.
  • The subject is a non-smoker for at least 12 months. If a former smoker, the reason for stopping must be evaluated.
  • Females who are physically incapable of childbearing defined as postmenopausal, or surgically sterile (hysterectomy, bilateral tubal ligation, bilateral oophorectomy or an Essure procedure). Appropriate documentation (ex; medical record) of the surgical sterilization procedure to be obtained and held within the subject's study file.
  • The subject must agree to comply with the drawing of blood samples for the PK assessments.
  • The subject is willing and able to comply with all testing and requirements defined in the protocol.
  • The subject is willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit.

Exclusion criteria

  • The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator.
  • The subject has had a clinically significant illness within 30 days of Check-in.
  • The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
  • The subject has used any prescription medication within 14 days of dosing or overthe- counter (OTC) medication within 48 h of dosing or intends to use any prescription medication or OTC medication during the study that may interfere with the evaluation of study medication.
  • The subject has used alcohol, caffeine or xanthine-containing products 48 h before dosing or intends to use any of these products during the study.
  • The subject has used grapefruit, grapefruit juice, or grapefruit-containing products days before dosing or intends to use any of these products during the study.
  • The subject has a history of substance abuse or a positive ethanol breath test, urine cotinine, or urine drug screen at screening or at check-in. The subject has a positive serum hepatitis B surface antigen or positive HCV antibody test at the Screening Visit.
  • The subject has a positive HIV test at the Screening Visit.
  • Female subject is pregnant or breastfeeding.
  • The subject has received an investigational drug within 30 days of Check-in.
  • The subject has donated or lost a significant volume of blood (>450 mL) within 4 weeks prior to the study.
  • The subject is unwilling to reside in the study unit for the duration of the study or to cooperate fully with the investigator or site personnel.
  • The subject has an AST/ALT or total bilirubin greater than the ULN. One repeat test will be allowed.

Treatment and study plan

50 mg PTI-125

Drug

PTI-125 50 mg Oral Solution

100 mg PTI-125

Drug

PTI-125 100 mg Oral Solution

200 mg PTI-125

Drug

PTI-125 200 mg Oral Solution

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The peak drug concentration will be obtained directly from the data without interpolation.

  2. Time to Maximum Plasma Concentration (Tmax) (Tmax)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The time to peak drug concentration will be obtained directly from the data without interpolation

  3. Time to Last Quantifiable Plasma Concentration (Tlast)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The time to the last quantifiable drug concentration will be obtained directly from the data without interpolation.

  4. Last Quantifiable Plasma Concentration (Clast)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The concentration of the last quantifiable drug will be obtained directly from the data without interpolation concentration

  5. Elimination Rate Constant (λz)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The elimination rate constant (λz) will be calculated.

  6. Termination Elimination Half-Life (T1/2)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The terminal elimination half-life (T1/2) will be calculated.

  7. Area Under the Curve (AUC)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The AUC from time zero to the time of the last quantifiable concentration (AUClast) will be calculated.

  8. Area Under the Curve to Infinity (AUCinf)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The AUC from time zero extrapolated to infinity (AUCinf) will be calculate.

  9. Percent Extrapolated of Area Under the Curve to Infinity (AUCextrap[%]).

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The percentage of AUCinf based on extrapolation (AUCextrap[%]).

  10. Oral Clearance (Cl/F)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    The apparent oral clearance will be calculated.

  11. Volume of Distribution (Vz/F)

    Time frame: Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.

    Vz/F, apparent volume of distribution will be calculated.

Sponsors and collaborators

Lead sponsor

Pain Therapeutics

Industry

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Important dates

Study start
2017
Primary completion
2017
Study completion
2018
First posted
Dec 21, 2018
Registry last updated
May 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.